Roles of the hepcidin-ferroportin axis and iron in cancer

European Journal of Cancer Prevention

Volumn 23, Issue 2, 2014, Pages 122-133

  Wu, Xian Ning ^a   Su, Dan ^b   Wang, Li ^a   Yu, Feng Lei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

cancer related anemia; ferroportin; hepcidin; iron metabolism

Indexed keywords

BONE MORPHOGENETIC PROTEIN 6; CD71 ANTIGEN; FERROPORTIN; FERROPORTIN 1A; FERROPORTIN 1B; HEPCIDIN; IRON; IRON REGULATORY PROTEIN 1; IRON REGULATORY PROTEIN 2; MESSENGER RNA; REACTIVE OXYGEN METABOLITE; TRANSFERRIN; TRANSFERRIN RECEPTOR 2; UNCLASSIFIED DRUG;

ANEMIA; BREAST CANCER; CANCER PATIENT; CARCINOGENESIS; DISEASE ASSOCIATION; DOWN REGULATION; ENDOCYTOSIS; FENTON REACTION; HUMAN; INTERNALIZATION; IRON METABOLISM; IRON TRANSPORT; LIVER CELL; MOLECULAR INTERACTION; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PLACENTAL TRANSFER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; TUMOR MICROENVIRONMENT; UBIQUITINATION; UPREGULATION;

ANIMALS; CATION TRANSPORT PROTEINS; HEPCIDINS; HUMANS; IRON; METABOLIC NETWORKS AND PATHWAYS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84893771702     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e3283627f14     Document Type: Review

References (120)

1. Abboud S, Haile DJ (2000). A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 275:19906-19912.
2. Andriopoulos B Jr, Corradini E, Xia Y, Faasse SA, Chen S, Grgurevic L, et al. (2009). BMP6 is a key endogenous regulator of hepcidin expression and iron metabolism. Nat Genet 41:482-487.
3. Babitt JL, Huang FW,Wrighting DM, Xia Y, Sidis Y, Samad TA, et al. (2006). Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 38:531-539.
4. Babitt JL, Huang FW, Xia Y, Sidis Y, Andrews NC, Lin HY (2007). Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balance. J Clin Invest 117:1933-1939.
5. Barbouti A, Doulias PT, Zhu BZ, Frei B, Galaris D (2001). Intracellular iron, but not copper, plays a critical role in hydrogen peroxide-induced DNA damage. Free Radic Biol Med 31:490-498.
6. Bertout JA, Patel SA, Simon MC (2008). The impact of O2 availability on human cancer. Nat Rev Cancer 8:967-975.
7. Bienz M, Clevers H (2000). Linking colorectal cancer to Wnt signaling. Cell 103:311-320.
8. Birgegard G, Gascon P, Ludwig H (2006). Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European Cancer Anaemia Survey. Eur J Haematol 77:378-386.
9. Brookes MJ, Boult J, Roberts K, Cooper BT, Hotchin NA, Matthews G, et al. (2008). A role for iron in Wnt signalling. Oncogene 27:966-975.
10. Butterfield AM, Luan P,Witcher DR, Manetta J, Murphy AT,Wroblewski VJ, et al. (2010). A dual-monoclonal sandwich ELISA specific for hepcidin-25. Clin Chem 56:1725-1732.
11. Caro JJ, Salas M,Ward A, Goss G (2001). Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91:2214-2221.
12. Casey JL, Hentze MW, Koeller DM, Caughman SW, Rouault TA, Klausner RD, et al. (1988). Iron-responsive elements: regulatory RNA sequences that control mRNA levels and translation. Science 240:924-928.
13. Cheng PP, Sun ZZ, Jiang F, Tang YT, Jiao XY (2012). Hepcidin expression in patients with acute leukaemia. Eur J Clin Invest 42:517-525.
14. Corna G, Campana L, Pignatti E, Castiglioni A, Tagliafico E, Bosurgi L, et al. (2010). Polarization dictates iron handling by inflammatory and alternatively activated macrophages. Haematologica 95:1814-1822.
15. Courselaud B, Pigeon C, Inoue Y, Inoue J, Gonzalez FJ, Leroyer P, et al. (2002). C/EBPalpha regulates hepatic transcription of hepcidin, an antimicrobial peptide and regulator of iron metabolism. Cross-talk between C/EBP pathway and iron metabolism. J Biol Chem 277:41163-41170.
16. Darnell G, Richardson DR (1999). The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood 94: 781-792.
17. De Domenico I, Nemeth E, Nelson JM, Phillips JD, Ajioka RS, Kay MS, et al. (2008). The hepcidin-binding site on ferroportin is evolutionarily conserved. Cell Metab 8:146-156.
18. Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H (2002). Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med 32:1102-1115.
19. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, et al. (2000). Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403:776-781.
20. Donovan A, Lima CA, Pinkus JL, Pinkus GS, Zon LI, Robine S, et al. (2005). The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab 1:191-200.
21. Edgren G, Bagnardi V, Bellocco R, Hjalgrim H, Rostgaard K, Melbye M, et al. (2010). Pattern of declining hemoglobin concentration before cancer diagnosis. Int J Cancer 127:1429-1436.
22. Epsztejn S, Glickstein H, Picard V, Slotki IN, Breuer W, Beaumont C, et al. (1999). H-ferritin subunit overexpression in erythroid cells reduces the oxidative stress response and induces multidrug resistance properties. Blood 94:3593-3603.
23. Faquin WC, Schneider TJ, Goldberg MA (1992). Effect of inflammatory cytokines on hypoxia-induced erythropoietin production. Blood 79:1987-1994.
24. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P, et al. (2005). Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20:2189-2199.
25. Fischer I, Gagner JP, Law M, Newcomb EW, Zagzag D (2005). Angiogenesis in gliomas: biology and molecular pathophysiology. Brain Pathol 15: 297-310.
26. Frazer DM, Anderson GJ (2003). The orchestration of body iron intake: how and where do enterocytes receive their cues? Blood Cells Mol Dis 30:288-297.
27. Fujita N, Sugimoto R, Ma N, Tanaka H, Iwasa M, Kobayashi Y, et al. (2008). Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J Viral Hepat 15:498-507.
28. Galaris D, Skiada V, Barbouti A (2008). Redox signaling and cancer: the role of 'labile' iron. Cancer Lett 266:21-29.
29. Ganz T (2004). Hepcidin in iron metabolism. Curr Opin Hematol 11:251-254.
30. Ganz T (2005). Hepcidin - a regulator of intestinal iron absorption and iron recycling by macrophages. Best Pract Res Clin Haematol 18:171-182.
31. Ganz T (2011). Hepcidin and iron regulation, 10 years later. Blood 117: 4425-4433.
32. Ganz T, Nemeth E (2009). Iron sequestration and anemia of inflammation. Semin Hematol 46:387-393.
33. Gao J, Lovejoy D, Richardson DR (1999). Effect of iron chelators with potent anti-proliferative activity on the expression of molecules involved in cell cycle progression and growth. Redox Rep 4:311-312.
34. Goswami T, Andrews NC (2006). Hereditary hemochromatosis protein, HFE, interaction with transferrin receptor 2 suggests a molecular mechanism for mammalian iron sensing. J Biol Chem 281:28494-28498.
35. Groopman JE, Itri LM (1999). Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 91:1616-1634.
36. Grotto HZ (2008). Anaemia of cancer: an overview of mechanisms involved in its pathogenesis. Med Oncol 25:12-21.
37. Hanninen MM, Haapasalo J, Haapasalo H, Fleming RE, Britton RS, Bacon BR, et al. (2009). Expression of iron-related genes in human brain and brain tumors. BMC Neurosci 10:36.
38. Hashizume M, Uchiyama Y, Horai N, Tomosugi N, Mihara M (2010). Tocilizumab a humanized anti-interleukin-6 receptor antibody, improved anemia in monkey arthritis by suppressing IL-6-induced hepcidin production. Rheumatol Int 30:917-923.
39. Hentze MW, Kuhn LC (1996). Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 93:8175-8182.
40. Hentze MW, Muckenthaler MU, Galy B, Camaschella C (2010). Two to tango: regulation of mammalian iron metabolism. Cell 142:24-38.
41. Hohaus S, Massini G, Giachelia M, Vannata B, Bozzoli V, Cuccaro A, et al. (2010). Anemia in Hodgkin's lymphoma: the role of interleukin-6 and hepcidin. J Clin Oncol 28:2538-2543.
42. Johnson MB, Chen J, Murchison N, Green FA, Enns CA (2007). Transferrin receptor 2: evidence for ligand-induced stabilization and redirection to a recycling pathway. Mol Biol Cell 18:743-754.
43. Kalinowski DS, Richardson DR (2005). The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev 57:547-583.
44. Kamai T, Tomosugi N, Abe H, Arai K, Yoshida K (2009). Increased serum hepcidin-25 level and increased tumor expression of hepcidin mRNA are associated with metastasis of renal cell carcinoma. BMC Cancer 9:270.
45. Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL, Kim JS, et al. (2011). Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-kappaB pathway, and MMP-9 expression. Exp Cell Res 317:1746-1762.
46. Kautz L, Meynard D, Monnier A, Darnaud V, Bouvet R, Wang RH, et al. (2008). Iron regulates phosphorylation of Smad1/5/8 and gene expression of Bmp6, Smad7, Id1, and Atoh8 in the mouse liver. Blood 112:1503-1509.
47. Kemna EH, Tjalsma H, Podust VN, Swinkels DW (2007). Mass spectrometrybased hepcidin measurements in serum and urine: analytical aspects and clinical implications. Clin Chem 53:620-628.
48. Kijima H, Sawada T, Tomosugi N, Kubota K (2008). Expression of hepcidin mRNA is uniformly suppressed in hepatocellular carcinoma. BMC Cancer 8:167.
49. Klausner RD, Rouault TA, Harford JB (1993). Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 72:19-28.
50. Kokorina NA, Zakharkin SO, Krebsbach PH, Nussenbaum B (2011). Treatment effects of rhBMP-2 on invasiveness of oral carcinoma cell lines. Laryngoscope 121:1876-1880.
51. Koptyra M, Falinski R, Nowicki MO, Stoklosa T, Majsterek I, Nieborowska-Skorska M, et al. (2006). BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108:319-327.
52. Kovacevic Z, Richardson DR (2006). The metastasis suppressor, Ndrg-1: a new ally in the fight against cancer. Carcinogenesis 27:2355-2366.
53. Krause A, Neitz S, Magert HJ, Schulz A, Forssmann WG, Schulz-Knappe P, et al. (2000). LEAP-1, a novel highly disulfide-bonded human peptide, exhibits antimicrobial activity. Febs Lett 480:147-150.
54. Kwok JC, Richardson DR (2002). The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol 42:65-78.
55. Laurent-Puig P, Zucman-Rossi J (2006). Genetics of hepatocellular tumors. Oncogene 25:3778-3786.
56. Lee KB, Murray SS, Duarte ME, Spitz JF, Johnson JS, Song KJ, et al. (2011). Effects of the bone morphogenetic protein binding protein spp24 (secreted phosphoprotein 24 kD) on the growth of human lung cancer cells. J Orthop Res 29:1712-1718.
57. Leibold EA, Munro HN (1988). Cytoplasmic protein binds in vitro to a highly conserved sequence in the 50 untranslated region of ferritin heavy- and lightsubunit mRNAs. Proc Natl Acad Sci USA 85:2171-2175.
58. Levine AJ, Momand J, Finlay CA (1991). The p53 tumour suppressor gene. Nature 351:453-456.
59. Lin L, Goldberg YP, Ganz T (2005). Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin. Blood 106:2884-2889.
60. Liu XB, Yang F, Haile DJ (2005). Functional consequences of ferroportin 1 mutations. Blood Cells Mol Dis 35:33-46.
61. Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. (2004). The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40:2293-2306.
62. Maegdefrau U, Arndt S, Kivorski G, Hellerbrand C, Bosserhoff AK (2011). Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma. Lab Invest 91:1615-1623.
63. Maes K, Nemeth E, Roodman GD, Huston A, Esteve F, Freytes C, et al. (2010). In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2. Blood 116:3635-3644.
64. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al. (2000). A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 5:299-309.
65. Mercadante S, Gebbia V, Marrazzo A, Filosto S (2000). Anaemia in cancer: pathophysiology and treatment. Cancer Treat Rev 26:303-311.
66. Merkofer M, Kissner R, Hider RC, Brunk UT, Koppenol WH (2006). Fenton chemistry and iron chelation under physiologically relevant conditions: electrochemistry and kinetics. Chem Res Toxicol 19:1263-1269.
67. Meynard D, Kautz L, Darnaud V, Canonne-Hergaux F, Coppin H, Roth MP (2009). Lack of the bone morphogenetic protein BMP6 induces massive iron overload. Nat Genet 41:478-481.
68. Montserrat E, Bosch F, Rozman C (1997). B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy. Ann Oncol 8 (Suppl 1): 93-101.
69. Moore LE, Pfeiffer RM, Zhang Z, Lu KH, Fung ET, Bast RC Jr (2012). Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer 118: 91-100.
70. Mukhtar RA, Nseyo O, Campbell MJ, Esserman LJ (2011). Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics. Expert Rev Mol Diagn 11:91-100.
71. Nakamura T, Scorilas A, Stephan C, Yousef GM, Kristiansen G, Jung K, et al. (2003). Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues. Br J Cancer 88:1101-1104.
72. Nemeth E (2010). Targeting the hepcidin-ferroportin axis in the diagnosis and treatment of anemias. Adv Hematol 2010:643-750.
73. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. (2004). Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306:2090-2093.
74. Nemeth E, Preza GC, Jung CL, Kaplan J, Waring AJ, Ganz T (2006). The Nterminus of hepcidin is essential for its interaction with ferroportin: structure- function study. Blood 107:328-333.
75. Nicolas G, Bennoun M, Devaux I, Beaumont C, Grandchamp B, Kahn A, et al. (2001). Lack of hepcidin gene expression and severe tissue iron overload in upstream stimulatory factor 2 (USF2) knockout mice. Proc Natl Acad Sci USA 98:8780-8785.
76. Nicolas G, Viatte L, Bennoun M, Beaumont C, Kahn A, Vaulont S (2002a). Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis 29:327-335.
77. Nicolas G, Chauvet C, Viatte L, Danan JL, Bigard X, Devaux I, et al. (2002b). The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest 110:1037-1044.
78. Niederkofler V, Salie R, Arber S (2005). Hemojuvelin is essential for dietary iron sensing, and its mutation leads to severe iron overload. J Clin Invest 115:2180-2186.
79. Pak M, Lopez MA, Gabayan V, Ganz T, Rivera S (2006). Suppression of hepcidin during anemia requires erythropoietic activity. Blood 108:3730-3735.
80. Pantopoulos K (2004). Iron metabolism and the IRE/IRP regulatory system: an update. Ann N Y Acad Sci 1012:1-13.
81. Park CH, Valore EV,Waring AJ, Ganz T (2001). Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J Biol Chem 276:7806-7810.
82. Pigeon C, Ilyin G, Courselaud B, Leroyer P, Turlin B, Brissot P, et al. (2001). A new mouse liver-specific gene, encoding a protein homologous to human antimicrobial peptide hepcidin, is overexpressed during iron overload. J Biol Chem 276:7811-7819.
83. Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, et al. (2010). Ferroportin and iron regulation in breast cancer progression and prognosis. Sci Transl Med 2:43r-56r.
84. Pogribny IP (2010). Ferroportin and hepcidin: a new hope in diagnosis, prognosis, and therapy for breast cancer. Breast Cancer Res 12:314.
85. Poli M, Girelli D, Campostrini N, Maccarinelli F, Finazzi D, Luscieti S, et al. (2011). Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood 117:997-1004.
86. Ramey G, Deschemin JC, Vaulont S (2009). Cross-talk between the mitogen activated protein kinase and bone morphogenetic protein/hemojuvelin pathways is required for the induction of hepcidin by holotransferrin in primary mouse hepatocytes. Haematologica 94:765-772.
87. Recalcati S, Locati M, Marini A, Santambrogio P, Zaninotto F, Pizzol MDe, et al. (2010). Differential regulation of iron homeostasis during human macrophage polarized activation. Eur J Immunol 40:824-835.
88. Renton FJ, Jeitner TM (1996). Cell cycle-dependent inhibition of the proliferation of human neural tumor cell lines by iron chelators. Biochem Pharmacol 51:1553-1561.
89. Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB (2009). Cancer cell iron metabolism and the development of potent iron chelators as antitumour agents. Biochim Biophys Acta 1790:702-717.
90. Rivera S, Nemeth E, Gabayan V, Lopez MA, Farshidi D, Ganz T (2005). Synthetic hepcidin causes rapid dose-dependent hypoferremia and is concentrated in ferroportin-containing organs. Blood 106:2196-2199.
91. Sasu BJ, Li H, Rose MJ, Arvedson TL, Doellgast G, Molineux G (2010a). Serum hepcidin but not prohepcidin may be an effective marker for anemia of inflammation (AI). Blood Cells Mol Dis 45:238-245.
92. Sasu BJ, Cooke KS, Arvedson TL, Plewa C, Ellison AR, Sheng J, et al. (2010b). Antihepcidin antibody treatment modulates iron metabolism and is effective in a mouse model of inflammation-induced anemia. Blood 115:3616-3624.
93. Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C (2008). The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 8:502-511.
94. Song SN, Tomosugi N, Kawabata H, Ishikawa T, Nishikawa T, Yoshizaki K (2010). Down-regulation of hepcidin resulting from long-term treatment with an anti- IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease. Blood 116:3627-3634.
95. Sow FB, Alvarez GR, Gross RP, Satoskar AR, Schlesinger LS, Zwilling BS, et al. (2009). Role of STAT1, NF-kappaB, and C/EBPbeta in the macrophage transcriptional regulation of hepcidin by mycobacterial infection and IFNgamma. J Leukoc Biol 86:1247-1258.
96. Tan MG, Kumarasinghe MP, Wang SM, Ooi LL, Aw SE, Hui KM (2009). Modulation of iron-regulatory genes in human hepatocellular carcinoma and its physiological consequences. Exp Biol Med (Maywood) 234: 693-702.
97. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, et al. (2007). High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 13:1096-1101.
98. Tanno T, Porayette P, Sripichai O, Noh SJ, Byrnes C, Bhupatiraju A, et al. (2009). Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells. Blood 114:181-186.
99. Tanno T, Rabel A, Alleyne M, Lee YT, Dahut WL, Gulley JL, et al. (2011). Hepcidin, anaemia, and prostate cancer. BJU Int 107:678-679.
100. Thelander L, Reichard P (1979). Reduction of ribonucleotides. Annu Rev Biochem 48:133-158.
101. Thomas R, True LD, Lange PH, Vessella RL (2001). Placental bone morphogenetic protein (PLAB) gene expression in normal, pre-malignant and malignant human prostate: relation to tumor development and progression. Int J Cancer 93:47-52.
102. Tseng HH, Chang JG, Hwang YH, Yeh KT, Chen YL, Yu HS (2009). Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J Cancer Res Clin Oncol 135: 1413-1420.
103. Vokurka M, Krijt J, Sulc K, Necas E (2006). Hepcidin mRNA levels in mouse liver respond to inhibition of erythropoiesis. Physiol Res 55:667-674.
104. Vokurka M, Krijt J, Vavrova J, Necas E (2011). Hepcidin expression in the liver of mice with implanted tumour reacts to iron deficiency, inflammation and erythropoietin administration. Folia Biol (Praha) 57:248-254.
105. Wallace DF, Summerville L, Lusby PE, Subramaniam VN (2005). First phenotypic description of transferrin receptor 2 knockout mouse, and the role of hepcidin. Gut 54:980-986.
106. Wallace DF, Harris JM, Subramaniam VN (2010). Functional analysis and theoretical modeling of ferroportin reveals clustering of mutations according to phenotype. Am J Physiol Cell Physiol 298:C75-C84.
107. Ward DG, Roberts K, Brookes MJ, Joy H, Martin A, Ismail T, et al. (2008). Increased hepcidin expression in colorectal carcinogenesis. World J Gastroenterol 14:1339-1345.
108. Waters JS, O'Brien ME, Ashley S (2002). Management of anemia in patients receiving chemotherapy. J Clin Oncol 20:601-603.
109. Weiss G (2002). Pathogenesis and treatment of anaemia of chronic disease. Blood Rev 16:87-96.
110. Weiss G,Wachter H, Fuchs D (1995). Linkage of cell-mediated immunity to iron metabolism. Immunol Today 16:495-500.
111. Weizer-Stern O, Adamsky K, Margalit O, Ashur-Fabian O, Givol D, Amariglio N, et al. (2007). Hepcidin, a key regulator of iron metabolism, is transcriptionally activated by p53. Br J Haematol 138:253-262.
112. Wrighting DM, Andrews NC (2006). Interleukin-6 induces hepcidin expression through STAT3. Blood 108:3204-3209.
113. Wulfert M, Kupper AC, Tapprich C, Bottomley SS, Bowen D, Germing U, et al. (2008). Analysis of mitochondrial DNA in 104 patients with myelodysplastic syndromes. Exp Hematol 36:577-586.
114. Xia Y, Babitt JL, Sidis Y, Chung RT, Lin HY (2008). Hemojuvelin regulates hepcidin expression via a selective subset of BMP ligands and receptors independently of neogenin. Blood 111:5195-5204.
115. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, et al. (2008). Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4:33-41.
116. Yu Y, Kovacevic Z, Richardson DR (2007). Tuning cell cycle regulation with an iron key. Cell Cycle 6:1982-1994.
117. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, et al. (2008). Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 100: 996-1002.
118. Zhang AS, Enns CA (2009). Molecular mechanisms of normal iron homeostasis. Hematology Am Soc Hematol Educ Program 1:207-214.
119. Zhang AS, Yang F, Meyer K, Hernandez C, Chapman-Arvedson T, Bjorkman PJ, et al. (2008). Neogenin-mediated hemojuvelin shedding occurs after hemojuvelin traffics to the plasma membrane. J Biol Chem 283:17494-17502.
120. Zhang DL, Hughes RM, Ollivierre-Wilson H, Ghosh MC, Rouault TA (2009). A ferroportin transcript that lacks an iron-responsive element enables duodenal and erythroid precursor cells to evade translational repression. Cell Metab 9:461-473.